Publicly listed Chinese Biotech companies

MAB warns of lower than expected profits due to mini Budget turmoil

The Mortgage Advice Bureau (MAB) has warned that its profit before tax for this year may be “slightly below market ...

Trading “severely impacted” by mini-budget at MAB

Mortgage Advice Bureau (MAB) has said that it expects to report financial results "slightly below market expectations" as a ...

Prothena nets more cash from Novo Nordisk; Khondrion fails to hit endpoint

A year after Novo Nordisk paid $100 million upfront to grab Prothena’s antibody and wider program in ATTR amyloidosis, the ...

Lilly's Covid-19 mAb no longer authorized due to Omicron subvariants, FDA says

The FDA on Wednesday announced that Eli Lilly's Covid-19 drug bebtelovimab is no longer authorized to treat Covid-19 because of the rising numbers of two new subvariants that the drug does not work ...

Biosimilars and Diversification Drive Innovation in mAb Manufacturing

Automation can reduce the labor required in addition to alleviating human error as a source of deviation from the GMP manufacturing process.

Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to ...

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod… https://t.co/XJhypL718Q

Eisai fields lecanemab safety questions in its full data release. BeiGene's Brukinsa betas Imbruvica in CLL. Shiono… https://t.co/bWbDMIwF0L

#42sTop42 2022-12-02 11:30 AM $BGNE BeiGene up 6.05% = $1.22 billion gain. https://t.co/QnzZPCl5hs (Dec 01) Why S… https://t.co/xu87Aj8sxq

Manager, Global Regulatory Affairs (GRA) Excellence – BeiGene – Remote via BN Briefs US - 5+ years' experience in w… https://t.co/98gl1lGWJ5

Eisai, BeiGene, ShionogiFierce Pharma #Asia [ https://t.co/B5WJx1x0El ] Just as Shionogi filed its #Covid19 vaccine… https://t.co/VVhTcvLZy5

Beigene. Annuncia la disponibilità in Italia di “BRUKINSA®” https://t.co/t7DNSJZQVO via @24 Ore News

What stocks might make more money? Compare $BGNE vs. $OTIS. #BeiGene https://t.co/2xE909UnnL https://t.co/9AAypO9qi6

Director, Data Operations and Services at BeiGene BeiGene continues to grow at a rapid pace with challenging and ex… https://t.co/KJeEBmzEDu

Analyst Ratings for Imago BioSciences

Within the last quarter, Imago BioSciences (NASDAQ:IMGO) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Imago BioSciences ...

Heralded Alzheimer’s Drug Works, but Safety Concerns Loom

Eisai and Biogen share clinical trial data confirming that lecanemab slows mental decline amid reports of potentially related ...

There are ways to conquer ‘vacation guilt’ in the always-on American workplace

Even if we’re on vacation halfway across the globe, we can check e-mails and hop on Zoom calls at the click of a button — a ...

Cambridge Cognition unveils Chinese expansion plans

Cambridge Cognition Holdings PLC (AIM:COG) has inked a strategic partnership that provides it with a low-cost entry to China, ...

Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat ...

The 2022 Access to Medicine Index (AtMI) ranks top pharmaceuticals globally

Top three pharmaceuticals include GSK, Johnson & Johnson and AstraZeneca -The report shows that more pharmaceuticals are ...